Vision Fund investment portfolio company Neuron23's logo

Neuron23 is using data and genomics to create precision medicines that fight debilitating diseases.

Leadership
Nancy StaglianoPhD
Fund
SVF2
Status
Private
Sector
Health Tech
Region
Americas

Insights
Roundup
Data and ML are creating a golden age of drug discovery

The biotech sector is poised to reap the benefits of the AI revolution, with lifesaving effects

Q&A
Neuron23's CEO Nancy Stagliano: Bringing AI to Life

Serial entrepreneur and CEO Nancy Stagliano talks about company building and using machine learning to develop individualized therapies.